Kamaria Lee
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (5)
PURPOSE Although significant differences in health care outcomes remain between low-middle–income countries and high-income countries, access to mobile devices is comparable. Interactive, patient-centric mobile health (mHealth) technology interventions may mitigate the increasing cancer burden in sub-Saharan Africa. However, these interventions' distribution, efficacy, and feasibility in the region are unknown. METHODS We compiled literature on two-way, patient-centric mHealth technology in sub-Saharan Africa. We searched online databases for studies completed in sub-Saharan Africa with mHealth interventions (inception to July 23, 2024). Two authors independently completed title/abstract screening. Inclusion criteria were sub-Saharan African setting, age 13 years or older with any health condition, two-way mobile communication, and outcomes studies. Studies that passed title/abstract screening underwent full-text review by two independent authors. Discrepancies were resolved through consensus. Data extraction/review was completed using Covidence software and Microsoft Excel. RESULTS We retrieved 1,380 unique citations. After screening/review, the final sample size was 37. Randomized controlled trials were most common (n = 20). A plurality took place in Kenya. HIV was the most common condition (n = 30). Interventions included messages about medication/appointment adherence and patient status. Most studies (32 of 37 [86%]) had at least one positive finding. Study characteristics varied widely for those with positive findings, but using various message frequencies, or peer navigators/social supporters increased success. All studies with no positive findings were randomized controlled trials; four of the five were on HIV. CONCLUSION Most two-way, patient-centric mHealth interventions in sub-Saharan Africa have been successful by at least one measure. Interventions have primarily been for patients with HIV. No studies have focused on cancer. With the increasing cancer burden in sub-Saharan Africa, an understanding of mHealth in oncologic settings is greatly needed.
Year:
2025
Background Little is known about pseudoprogression after proton therapy (PT) for pediatric spinal tumors. Clinical consequences are significant if it is not appropriately identified. We report the incidence of pseudoprogression in pediatric spinal pilocytic astrocytoma (sPA) and myxopapillary ependymoma (MPE) after PT at our institution. Procedure Medical charts were retrospectively reviewed for patients <18 years old who received PT from 2007 to 2019 for sPA or MPE. Patients with gross disease at the time of PT and at least 6 months of follow‐up were included. Demographic, tumor, and treatment characteristics were tabulated. Two neuroradiologists scored pre‐ and post‐PT magnetic resonance images to assess for pseudoprogression, and the incidence of pseudoprogression was determined. Results Fifteen patients were included (nine with sPA, six with MPE). Median age of patients with sPA was 10.1 years and 12.7 years for patients with MPE. Median prescribed dose was 45.0 cobalt‐60 Gy equivalents (GyRBE) (range, 39.6–50.4) for sPA and 50.4 GyRBE for MPE (range, 45.0–54.0). Within 6 months post‐PT, pseudoprogression occurred in six of nine patients (67%) with sPA, and three were symptomatic. No patients with MPE developed pseudoprogression ( p < 0.03). Conclusions Pseudoprogression may occur within 6 months after PT for sPA but is not likely for MPE, even with a higher median PT dose. As pseudoprogression can be clinically challenging, clinicians should be aware of this possibility to provide appropriate guidance for patients and families.
Year:
2025
Financial toxicity, or the financial burden patients experience because of medical costs, can lead to negative patient effects including lower quality of life, compromised clinical care, and worse health outcomes. People with cancer and survivors are more likely to have financial toxicity than those without cancer, and patients with breast cancer are uniquely at risk. Patients with breast cancer often require multimodal treatment (surgery, radiation, and/or systemic therapy) and adjuvant hormonal therapy can continue for years after primary treatment. With improved disease outcomes, patients with breast cancer have prolonged survivorship often lasting decades but may carry chronic toxicities from treatment; both ongoing treatment of metastatic disease and long-term surveillance include continued tests, imaging, and medical visits that add to the cumulative burden on patients and their families. Additionally, breast cancer predominately affects women, who are more likely to have dual caregiver responsibilities, and increasingly is diagnosed in younger patients, who may have fertility preservation expenses and are more likely to experience education and/or employment disruption. When faced with high costs, patients may face difficult decisions regarding what sacrifices they are willing to endure to receive care. Interventions designed to reduce financial toxicity are moving out of the pilot phase, and ongoing randomized trials are expected to provide evidence into the effectiveness of financial navigation programs. Further work to address financial toxicity in breast cancer at the patient-provider, institutional, and governmental levels is needed for comprehensively better financial outcomes and quality of life.
Year:
2025
Background: With extended lifespans for people with human immunodeficiency virus (PWH), there is a corresponding increased burden of chronic illnesses, including cancer. Our objective was to estimate the excess mortality among PWH with cancer compared with people without HIV (PWoH), accounting for the higher background mortality in the general PWH population. Methods: We identified 39,000 PWH and 387,767 demographically matched PWoH in three integrated healthcare systems from 2000 to 2016. We estimated excess mortality among PWH with cancer, computed as the cancer mortality rate difference-in-difference comparing PWH and PWoH. We evaluated five cancer groups: any cancer; virus-, human papillomavirus–, and Epstein–Barr virus –related cancers; virus-unrelated cancers, and common individual cancers. We fitted a multivariable additive Poisson model to estimate excess mortality among PWH with cancer. Results: PWH with any cancer had excess mortality compared with PWoH [41.3/1,000 person-years (py), 95% confidence interval (CI), 34.0–48.7]. The highest excess mortality was observed for Epstein–Barr virus–related cancers (63.2/1,000 py, 95% CI, 47.8–78.7), lung cancer (147.7/1,000 py, 95% CI, 41.1–254.3), and non–Hodgkin lymphoma (70.5/1,000 py, 95% CI, 51.4–89.6). Excess mortality among PWH was attenuated from 2009 to 2016, and PWH with cancer had no excess mortality 5 years after diagnosis. Conclusion: PWH in care may have excess mortality from certain cancer types, although disparities may have attenuated over time and do not persist beyond 5 years after diagnosis. Impact: Findings may guide improved clinical practice and suggest further research is needed to investigate whether cancer treatment or other factors contribute to mortality disparities for PWH with cancer.
Year:
2024
Background: With extended lifespans for people with human immunodeficiency virus (PWH), there is a corresponding increased burden of chronic illnesses, including cancer. Our objective was to estimate the excess mortality among PWH with cancer compared with people without HIV (PWoH), accounting for the higher background mortality in the general PWH population. Methods: We identified 39,000 PWH and 387,767 demographically matched PWoH in three integrated healthcare systems from 2000 to 2016. We estimated excess mortality among PWH with cancer, computed as the cancer mortality rate difference-in-difference comparing PWH and PWoH. We evaluated five cancer groups: any cancer; virus-, human papillomavirus–, and Epstein–Barr virus –related cancers; virus-unrelated cancers, and common individual cancers. We fitted a multivariable additive Poisson model to estimate excess mortality among PWH with cancer. Results: PWH with any cancer had excess mortality compared with PWoH [41.3/1,000 person-years (py), 95% confidence interval (CI), 34.0–48.7]. The highest excess mortality was observed for Epstein–Barr virus–related cancers (63.2/1,000 py, 95% CI, 47.8–78.7), lung cancer (147.7/1,000 py, 95% CI, 41.1–254.3), and non–Hodgkin lymphoma (70.5/1,000 py, 95% CI, 51.4–89.6). Excess mortality among PWH was attenuated from 2009 to 2016, and PWH with cancer had no excess mortality 5 years after diagnosis. Conclusion: PWH in care may have excess mortality from certain cancer types, although disparities may have attenuated over time and do not persist beyond 5 years after diagnosis. Impact: Findings may guide improved clinical practice and suggest further research is needed to investigate whether cancer treatment or other factors contribute to mortality disparities for PWH with cancer.
Year:
2024
Collaborators (4)
Jennifer Kramer
Baylor College of Medicine
Elizabeth Chiao
Professor
The University of Texas MD Anderson Cancer Center
Lilie L. Lin
Associate Professor
The University of Texas MD Anderson Cancer Center
Fumiko Chino
The University of Texas MD Anderson Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.